From the wire: Rhenovia Pharma (Mulhouse, France) has filed two patent applications for RHEpatch, its electronic transdermal patch for people suffering from chronic diseases. Originally designed to deliver drugs to patients suffering from diseases of the nervous system, the RHEpatch has potential to impact the entire health sector, according to the company. The device provides continuous control of dosing, treatment time and duration of up to seven drugs. Control is achieved through a built-in electronic system preprogrammed by the physician. RHEpatch thus provides better control over the delivery of several drugs prescribed as a polytherapy, especially for the elderly, says the company.
RHEpatch is also designed to deliver combinations of compounds needed to treat complex nervous system diseases such as Alzheimer’s. It automatically controls the administration of drugs. Existing transdermal patches typically have passive drug-release systems.
The system was developed with industrial partner Portmann Instruments AG, a Swiss company specialised in high-precision instrumentation, as part of a three-year EU Eurostars programme.
The RHEpatch is now in the pre-industrialisation prototype stage. Following technological and biological proof-of-concept studies, Rhenovia seeks pharmaceutical, industrial and financial partners to move on to the industrialisation and licensing stage.